Japan Elaprase® Treatment (JET) study: Idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (Mucopolysaccharidosis II, MPS II)

Molecular Genetics and Metabolism

Volumn 99, Issue 1, 2010, Pages 18-25

  Okuyama, Torayuki ^a   Tanaka, Akemi ^b   Suzuki, Yasuyuki ^c   Ida, Hiroyuki ^d   Tanaka, Toju ^a   Cox, Gerald F ^e,f   Eto, Yoshikatsu ^d   Orii, Tadao ^g  

^a NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^b OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e GENZYME CORPORATION   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g GIFU UNIVERSITY   (Japan)

Author keywords

Clinical trial; Elaprase; Enzyme replacement therapy; Hunter syndrome; Idursulfase; Mucopolysaccharidosis II

Indexed keywords

GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE;

ABDOMINAL PAIN; ADULT; ARTICLE; CLINICAL ARTICLE; DYSPNEA; ERYTHEMA; FORCED EXPIRATORY VOLUME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE MASS; HUMAN; HUNTER SYNDROME; JOINT; LIVER WEIGHT; LYSOSOME STORAGE DISEASE; MALE; PRIORITY JOURNAL; RANGE OF MOTION; SPLEEN WEIGHT; SYNCOPE; URTICARIA; VALVULAR HEART DISEASE; WALKING; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; ENZYME REPLACEMENT; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; JAPAN; LIVER; MIDDLE AGED; MULTICENTER STUDY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; SPLEEN; TREATMENT OUTCOME; URINE; VITAL CAPACITY;

SYNCOPE;

ADULT; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FOLLOW-UP STUDIES; GLYCOSAMINOGLYCANS; HUMANS; IDURONATE SULFATASE; INFUSIONS, INTRAVENOUS; JAPAN; LIVER; MALE; MIDDLE AGED; MUCOPOLYSACCHARIDOSIS II; ORGAN SIZE; SPLEEN; TREATMENT OUTCOME; VITAL CAPACITY; YOUNG ADULT;

EID: 71649090838     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.08.006     Document Type: Article

References (31)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R. (Ed). The Metabolic and Molecular Bases of Inherited Disease (2001), McGraw Hill, New York 3421-3452
2. Martin R., Beck M., Eng C., Giugliani R., Harmatz P., Munoz V., and Muenzer J. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics 121 (2008) e377-386
3. Wraith J.E. Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II. Acta. Paediatr. Suppl. 97 (2008) 76-78
4. Lissens W., Seneca S., and Liebaers I. Molecular analysis in 23 Hunter disease families. J. Inherit. Metab. Dis. 20 (1997) 453-456
5. Kim C.H., Hwang H.Z., Song S.M., Paik K.H., Kwon E.K., Moon K.B., Yoon J.H., Han C.K., and Jin D.K. Mutational spectrum of the iduronate 2 sulfatase gene in 25 unrelated Korean Hunter syndrome patients: identification of 13 novel mutations. Hum. Mutat. 21 (2003) 449-450
6. Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K., Muzny D.M., Dugan-Rocha S.P., Nelson D.L., Pettersson U., and Gibbs R.A. Molecular and phenotypic variation in patients with severe Hunter syndrome. Hum. Mol. Genet. 6 (1997) 479-486
7. Vafiadaki E., Cooper A., Heptinstall L.E., Hatton C.E., Thornley M., and Wraith J.E. Mutation analysis in 57 unrelated patients with MPS II (Hunter's disease). Arch. Dis. Child. 79 (1998) 237-241
8. Li P., Bellows A.B., and Thompson J.N. Molecular basis of iduronate-2-sulphatase gene mutations in patients with mucopolysaccharidosis type II (Hunter syndrome). J. Med. Genet. 36 (1999) 21-27
9. Wilson P.J., Suthers G.K., Callen D.F., Baker E., Nelson P.V., Cooper A., Wraith J.E., Sutherland G.R., Morris C.P., and Hopwood J.J. Frequent deletions at Xq28 indicate genetic heterogeneity in Hunter syndrome. Hum. Genet. 86 (1991) 505-508
10. Yamada Y., Tomatsu S., Sukegawa K., Suzuki Y., Kondo N., Hopwood J.J., and Orii T. Mucopolysaccharidosis type II (Hunter disease): 13 gene mutations in 52 Japanese patients and carrier detection in four families. Hum. Genet. 92 (1993) 110-114
11. Ochiai T., Suzuki Y., Kato T., Shichino H., Chin M., Mugishima H., and Orii T. Natural history of extensive Mongolian spots in Mucopolysaccharidosis type II (Hunter syndrome): a survey among 52 Japanese patients. J. Eur. Acad. Dermatol. Venereol. 21 (2007) 1082-1085
12. Meikle P.J., Hopwood J.J., Claque A.E., and Carey W.F. Prevalence of lysosomal storage disorders, JAMA. 281 (1999) 249-254
13. Poorthuis B.J., Wevers R.A., Kleijer W.J., Groener J.E., de Jong J.G., van Weely S., Niezen-Koning K.E., and van Diggelen O.P. The frequency of lysosomal storage diseases in The Netherlands. Hum. Genet. 105 (1999) 151-156
14. Pinto R., Caseiro C., Lemos M., Lopes L., Fontes A., Ribeiro H., Pinto E., Silva E., Rocha S., Marcao A., Ribeiro I., Lacerda L., Ribeiro G., Amaral O., and Sa Miranda M.C. Prevalence of lysosomal storage diseases in Portugal. Eur. J. Hum. Genet. 12 (2004) 87-92
15. Baehner F., Schmiedeskamp C., Krummenauer F., Miebach E., Bajbouj M., Whybra C., Kohlschutter A., Kampmann C., and Beck M. Cumulative incidence rates of the mucopolysaccharidoses in Germany. J. Inherit. Metab. Dis. 28 (2005) 1011-1017
16. Vellodi A., Young E., Cooper A., Lidchi V., Winchester B., and Wraith J.E. Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22 (1999) 638-648
17. Kaye E.M. Lysosomal storage diseases. Curr. Treat. Options Neurol. 3 (2001) 249-256
18. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., and Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta. Paediatr. Suppl. 91 (2002) 98-99
19. Muenzer J., Gucsavas-Calikoglu M., McCandless S.E., Schuetz T.J., and Kimura A. A phase I/II clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Mol. Genet. Metab. 8 (2007) 329-337
20. Muenzer J., Wraith J.E., Beck M., Giugliani R., Harmatz P., Eng C.M., Vellodi A., Martin R., Ramaswami U., Gucsavas-Calikoglu M., Vijayaraghavan S., Wendt S., Puga A.C., Ulbrich B., Shinawi M., Cleary M., Piper D., Conway A.M., and Kimura A. A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome). Genet. Med. 8 (2006) 465-473
21. Standardization of spirometry. 1994 update. American Thoracic Society, Am. J. Respir. Crit. Care Med. 152 (1995) 1107-1136.
22. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories, ATS statement: guidelines for the six-minute walk test, Am. J. Respir. Crit. Care Med. 166 (2002) 111-117.
23. Fietze I., Dingli K., Diefenbach K., Douglas N.J., Glos M., Tallafuss M., Terhalle W., and Witt C. Night-to-night variation of the oxygen desaturation index in sleep apnoea syndrome. Eur. Resp. J. 24 (2004) 987-993
24. Enright P.L., and Sherrill D.L. Reference equations for the six-minute walk in healthy adults. Am. J. Respir. Crit. Care Med. 158 (1998) 1384-1387
25. Redelmeier D.A., Bayoumi A.M., Goldstein R.S., and Guyatt G.H. Interpreting small differences in functional status: the Six Minute Walk test in chronic lung disease patients. Am. J. Respir. Crit. Care Med. 155 (1997) 1278-1282
26. Lung function testing: selection of reference values and interpretative strategies. American Thoracic Society, Am. J. Rev. Respir. Dis. 144 (1991) 1202-1218. .
27. de Simone G., Muiesan M.L., Ganau A., Longhini C., Verdecchia P., Palmieri V., Agabiti-Rosei E., and Mancia G. Reliability and limitations of echocardiographic measurement of left ventricular mass for risk stratification and follow-up in single patients: the RES trial. J. Hypertens. 17 (1999) 1955-1963
28. J.E. Wraith, M.Scarpa, M. Beck, O.A. Bodamer, L. De Meirleir, N. Guffon, A.M. Lund, G. Malm, A.T. Van der Ploeg, J. Zeman, Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy, Eur. J. Pediatr. 167 (2008) 267-277 (Epub 2007 Nov 23).
29. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-l-iduronidase (laronidase). J. Pediatr. 144 (2004) 581-588
30. Clarke L.A., Wraith J.E., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Sidman M., Kakkis E.D., and Cox G.F. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 123 (2009) 229-240
31. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., and Kakkis E. S.J. Swiedler; MPS VI Phase 3 Study Group, Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 148 (2006) 533-539